MetaCap

Tarsus Pharmaceuticals (TARS) vs Vericel (VCEL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vericel (VCEL) has outperformed Tarsus Pharmaceuticals (TARS) over the past year, gaining 45.3% versus a loss of 8.3%. Over five years, TARS leads with a +192.0% price change compared with +50.1% for VCEL. Tarsus Pharmaceuticals is the larger company by market cap ($3.60 billion vs $2.94 billion), about 1.2 times the size.

On valuation, Vericel trades at a lower forward P/E (61.1x vs 339.6x for Tarsus Pharmaceuticals). Vericel converts more of its revenue into profit, with a net margin of 6.0% versus -14.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

TARS-8.35%VCEL+45.33%
+54%+10%-34%
Nov 21, 20251 yearNov 20, 2026
TARS+191.22%VCEL+29.75%
+278%+103%-72%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

TARS versus VCEL key metrics
MetricTARSVCEL
Share price$73.01$57.52
Market cap$3.60B$2.94B
1-day change-6.00%-1.27%
YTD return-10.83%+59.73%
1-year return-8.35%+45.33%
5-year return+192.04%+50.14%
P/E ratio (TTM)—89.88
Forward P/E339.5861.06
EPS (TTM)$-15.86$0.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$451.36M$276.26M
Revenue growth (YoY)+146.71%+16.45%
Net income (latest FY)$-66.42M$16.52M
Gross margin—74.42%
Operating margin-15.72%4.00%
Net margin-14.72%5.98%
52-week high$91.53$59.75
52-week low$53.89$28.95
Distance from 52-week high-20.23%-3.73%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+41.68%+13.75%
Average volume871.07K664.34K
Shares outstanding49.31M51.03M
Employees370398
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VCEL has outperformed TARS by 53.7 percentage points over the past year.
  • Vericel is more profitable, keeping 6.0 cents of every revenue dollar as net income versus -14.7 cents for Tarsus Pharmaceuticals.
  • Tarsus Pharmaceuticals grew revenue faster in its latest fiscal year (+146.71% vs +16.45%).

About Tarsus Pharmaceuticals

TARS stock →

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 370 employees

About Vericel

VCEL stock →

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 398 employees

TARS vs VCEL FAQ

Which is bigger, Tarsus Pharmaceuticals or Vericel?

Tarsus Pharmaceuticals (TARS) is larger, with a market capitalization of $3.60B compared with $2.94B for Vericel (VCEL).

Which stock has performed better over the past year, TARS or VCEL?

VCEL returned +45.33% over the past 12 months, compared with -8.35% for TARS (price return, excluding dividends). Past performance does not predict future results.

Are Tarsus Pharmaceuticals and Vericel in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons